echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Astellas' gene therapy takes another hit

    Astellas' gene therapy takes another hit

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Duchenne muscular dystrophy (DMD) is the most common type of progressive muscular dystrophy, with progressive and lethal features


    Duchenne muscular dystrophy (DMD) is caused by the absence or loss of function of dystrophin


    The gene encoding dystrophin is located at Xp21.


    Japanese pharmaceutical company Astellas has disclosed that it will discontinue its AT702, AT751 and AT753 gene therapy programs for Duchenne muscular dystrophy (DMD) based on recent preclinical study data


    The company's gene therapy approach for DMD uses an AAV vector encoding a modified U7 snRNA to deliver an antisense sequence designed to induce cells to skip the erroneous or misplaced genetic code in the dystrophin gene, thereby restoring functional dystrophin Production of atrophin


    The company's gene therapy approach for DMD uses an AAV vector encoding a modified U7 snRNA to deliver an antisense sequence designed to induce cells to skip the erroneous or misplaced genetic code in the dystrophin gene, thereby restoring functional dystrophin Production of atrophin


     

    Original source:

    Original source:

    https://firstwordpharma.


    https://firstwordpharma.
    com/story/5554133 https://firstwordpharma.
    com/story/5554133

    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.